NCT03894124View on ClinicalTrials.gov

Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

July 25, 2019

Study Completion Date

August 6, 2019

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Doravirine

Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.

Trial Locations (1)

SW10 9NH

Chelsea and Westminster Hospital NHS Foundation Trust, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Imperial College London

OTHER

collaborator

University of Liverpool

OTHER

lead

Chelsea and Westminster NHS Foundation Trust

OTHER

NCT03894124 - Pharmacokinetics of Plasma Doravirine Once Daily Over 72 Hours Following Drug Intake Cessation in Healthy Volunteers | Biotech Hunter | Biotech Hunter